Immune checkpoint inhibitors and the development of granulomatous reactions-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors and the development of granulomatous reactions

Published:2019-11 Issue:5 Volume:81 Page:1165-1175
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Cornejo Christine M.,Haun Paul,English Joseph,Rosenbach Misha

Publisher

Elsevier BV

Subject

Dermatology

Reference93 articles.

1. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies;Naidoo;Ann Oncol,2015

2. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study;O'Day;Ann Oncol,2010

3. Management of immune-related adverse events and kinetics of response with ipilimumab;Weber;J Clin Oncol,2012

4. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study;Wolchok;Lancet Oncol,2010

5. Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE). Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed December 17, 2017.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors and the orbit; two cases of reactive dacryoadenitis;Orbit;2024-08-07

2. Delayed Pembrolizumab-Associated Sarcoidosis;American Journal of Therapeutics;2024-07

3. Air pollution and incident sarcoidosis in central Pennsylvania;Journal of Toxicology and Environmental Health, Part A;2024-06-26

4. Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival;Respiratory Medicine;2024-06

5. Indurated Subcutaneous Thigh Nodules: Answer;The American Journal of Dermatopathology;2024-06